And a meta-analysis confirmed that dapagliflozin enhances liver function and glycemic control in patients with T2DM and fatty liver disease, as indicated by reductions in ALT, AST, fasting glucose, and HbA1c [175]. The gene discussed is GPT; the disease is fatty liver disease.